Schedule 13D ownership disclosure
Enliven Therapeutics Inc
Security class unavailable · CUSIP: 29337E102
Event date: 2024-04-02
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 8,951,463
- Percent of class
- 19.2000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-24-000350
- Form type
- SC 13D
- Filer
- Enliven Therapeutics, Inc.
- CIK
- CIK 1672619
- Filed
- Apr 04, 2024
- Reporting period
- Apr 02, 2024
- Description
- Schedule 13D beneficial ownership